JB Pharma stock hits 52-week high following stellar Q1 earnings report
Open Demat A/C JB Pharma shares surge nearly 3% to 52-Week high of ₹1,999 on strong Q1 earnings
Open Demat A/C JB Pharma revenue crosses ₹1,000 crore for the first time, up 12% YoY in Q1 FY25
Open Demat A/C
JB Pharma domestic sales rise 22% YoY, driving Q1 revenue growth despite flat international sale
Open Demat A/C JB Pharma EBITDA grows 20% YoY to ₹292 crore, EBITDA margin expands to 29% in Q1
Open Demat A/C JB Pharma net profit up 25% YoY to ₹177 crore, boosted by strong operational and revenue performance
Open Demat A/C JB Pharma forecasts operating margins of 26-28%, focuses on cost optimization
Open Demat A/C JB Pharma aims for India and CDMO business to contribute 75-80% of revenue in mid-term
Open Demat A/C JB Pharma projects market-beating growth for India business, Targeting 60% share of chronic therapies
Open Demat A/C With Our Subscription Plans
Open demat account in 5 minutes*
Open Demat A/C G-L92HWH8MZR